Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

MLA

Andriani, Alessandro, et al. “Treatment of Philadelphia-Negative Myeloproliferative Neoplasms in Accelerated/Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors.” Hematological Oncology, vol. 37, no. 3, Aug. 2019, pp. 291–95. EBSCOhost, https://doi.org/10.1002/hon.2635.

APA

Andriani, A., Elli, E., Trapè, G., Villivà, N., Fianchi, L., Di Veroli, A., Niscola, P., Centra, A., Anaclerico, B., Montanaro, G., Martini, V., Aroldi, A., Carmosino, I., Voso, M. T., Breccia, M., Montanaro, M., Foà, R., & Latagliata, R. (2019). Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematological Oncology, 37(3), 291–295. https://doi.org/10.1002/hon.2635

Chicago

Andriani, Alessandro, Elena Elli, Giulio Trapè, Nicoletta Villivà, Luana Fianchi, Ambra Di Veroli, Pasquale Niscola, et al. 2019. “Treatment of Philadelphia-Negative Myeloproliferative Neoplasms in Accelerated/Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors.” Hematological Oncology 37 (3): 291–95. doi:10.1002/hon.2635.